Success Stories: From Crop Crisis to Cutting-Edge Solutions: How a Plant Pathologist Earned EB1A Approval

Client’s Testimonial:

“Thank you so much! This is indeed wonderful news. I truly appreciate your kind support and the effort you put into preparing my application.”

On July 30^th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Researcher 5 in the Field of Plant Pathology (Approval Notice).

General Field: Plant Pathology

Position at the Time of Case Filing: Researcher 5

Country of Origin: India

State of Residence at the Time of Filing: Minnesota

Approval Notice Date: July 30^th, 2025

Processing Time: 11 months, 24 days

Case Summary:

We are pleased to share the success story of a plant pathology expert from India who secured EB1A (Alien of Extraordinary Ability) approval with the help of our team at NAILG. At the time of filing, the client held a Researcher 5 position and had established himself as a leader in developing innovative diagnostic tools and molecular strategies to combat plant viruses that threaten global agriculture.

Harnessing Biotechnology to Safeguard Agriculture

With a research portfolio focused on improving plant health through next-generation biotechnological tools, he has made notable advancements in viral disease diagnostics and gene editing systems. His work integrates artificial intelligence, CRISPR/Cas genome editing, and plant virology to develop precision tools for early detection and targeted gene silencing in affected crops. These technologies have immense value in ensuring agricultural sustainability, mitigating crop loss, and supporting food security on a global scale.

The client has published 48 peer-reviewed journal articles, 10 book chapters, and 7 abstracts, earning 755 citations across scientific literature. Several of his articles are ranked among the top 10% of most cited in their discipline for their respective publication years, underscoring the high impact and visibility of his contributions.

Respected by Global Scientific Communities

As part of his service to the scientific community, he has performed at least 21 peer reviews for leading journals such as Plant Biotechnology Journal and Sensors and Actuators B: Chemical. He has also served on editorial boards and contributed as a reviewer for grant applications submitted to international scientific bodies.

His achievements were supported by compelling testimonial letters. One recommender noted that his research “sets new standards in the precision and efficiency of plant disease management” and that his work “bolsters the U.S.’s standing in global agricultural markets by ensuring healthier crops and more reliable yields.”

Establishing Extraordinary Ability

To secure this EB1A petition, our legal team at NAILG strategically established that the client met three key evidentiary criteria: authorship of scholarly articles, original contributions of major significance, and service as a judge of others’ work. We demonstrated how his research has brought measurable benefits to the field of plant pathology and has direct implications for improving agricultural resilience in the United States.

His prior success in obtaining competitive research grants from premier funding agencies further emphasized his recognition and leadership in the field.

Looking Ahead

With his EB1A petition approved, the client is now well positioned to continue his groundbreaking work in the United States. At NAILG, we are proud to have contributed to this milestone and look forward to the continued impact of his research on sustainable agriculture and global food systems.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.